GSK's earnings per share (EPS) forecast has been lowered by UBS by approximately 5% due to expected weakness in third-quarter performance.

The decline in EPS is attributed to recent decreases in US vaccine sales and the underperformance of the Chinese Shingrix vaccine.

Looking ahead to 2024, GSK is projected to experience sales growth of around 7% to 9%, an increase from the previous estimate of 5% to 7%. Core EBIT is expected to rise between 11% and 13%, up from the earlier forecast of 9% to 11%. Additionally, core EPS is anticipated to grow by 10% to 12%, compared to the prior estimate of 8% to 10%. The resolution of the Zantac litigation has not affected the price target.